Protalix BioTherapeutics, Inc.
PLX
$1.98
$0.021.02%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 233.73% | -49.93% | -0.60% | 16.21% | 169.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 233.73% | -49.93% | -0.60% | 16.21% | 169.82% |
| Cost of Revenue | -49.55% | 44.51% | -0.61% | -37.92% | 214.37% |
| Gross Profit | 1,432.49% | -837.37% | -0.59% | 143.60% | 68.67% |
| SG&A Expenses | 17.21% | 17.57% | 12.87% | -24.68% | -16.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.60% | 25.17% | 12.54% | -8.90% | 65.71% |
| Operating Income | 610.16% | -164.61% | -46.60% | 148.29% | 14.64% |
| Income Before Tax | 666.48% | -165.28% | -41.74% | 129.09% | 21.15% |
| Income Tax Expenses | 2,599.12% | -11.44% | -119.11% | 820.29% | 18.12% |
| Earnings from Continuing Operations | 606.13% | -184.76% | -27.22% | 107.44% | 21.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 606.13% | -184.76% | -27.22% | 107.44% | 21.24% |
| EBIT | 610.16% | -164.61% | -46.60% | 148.29% | 14.64% |
| EBITDA | 667.25% | -156.62% | -42.06% | 172.68% | 16.21% |
| EPS Basic | 586.02% | -174.81% | -32.50% | 106.98% | 24.96% |
| Normalized Basic EPS | 644.41% | -157.60% | -45.87% | 127.32% | 24.94% |
| EPS Diluted | 540.00% | -208.81% | -1.00% | 106.64% | 20.51% |
| Normalized Diluted EPS | 623.36% | -185.62% | -41.55% | 126.29% | 24.94% |
| Average Basic Shares Outstanding | 4.23% | 13.23% | 7.79% | 7.31% | 4.90% |
| Average Diluted Shares Outstanding | 8.40% | -23.79% | -0.50% | 10.86% | 4.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |